A broad-spectrum antibody therapeutic against flavivirus infections.
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN272201600028C
- Awardee
-
Abviro LLC UEI K3L6KXJ9B6M7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $29,175,011
Award facts
- Opportunity
-
- NIAIDDMIDNIHAI2015037 Solicitation number
- Development of Therapeutic Products for Biodefense & Emerging Infectious Diseases Award Notice · Posted Jun 17, 2015
- Contract value 100% obligated
- $29,175,011.23 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 13 offers Basic Research
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Bethesda, MD 20814, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$229,705 | |
| Funding Only Action | -$34,173 | |
| Funding Only Action | -$1,912 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $9,049 | |
| Funding Only Action | -$122,304 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $2,600,780 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Exercise an Option | $3,186,726 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $2,067,352 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $3,314,565 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $3,878,629 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $9,353,702 | |
| Other Administrative Action | $0 | |
| Original award | $5,152,302 |
Show all 23
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $29.2 million cost-plus-fixed-fee contract to Abviro LLC on September 19, 2016, for the development of a broad-spectrum monoclonal antibody therapeutic against flavivirus infections. The contract, which concluded on September 30, 2022, focused on developing a safe, injectable therapeutic candidate designated AV-1. Abviro LLC, the prime contractor, performed work at its location in Bethesda, Maryland. This contract was not designated as a set-aside.
This contract supported NIAID's mission to develop medical countermeasures against infectious diseases of public health significance. Flaviviruses, including dengue, Zika, and West Nile virus, represent a significant threat to global health, and the development of a broad-spectrum antibody therapeutic would provide a potential treatment option applicable across multiple flavivirus-caused infections. The cost-plus-fixed-fee structure aligned with the research and development nature of the effort, allowing for flexibility while containing government costs through the fixed fee component.
Quick answers
Who was awarded contract HHSN272201600028C?
HHSN272201600028C was awarded to Abviro LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 19, 2016.
How much is contract HHSN272201600028C worth?
The government has obligated $29,175,011 on HHSN272201600028C.
Was contract HHSN272201600028C competed?
The extent of competition for HHSN272201600028C was full and open competition. The government received 13 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award